These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 30770221)

  • 21. Antibody persistence and booster responses 24-36 months after different 4CMenB vaccination schedules in infants and children: A randomised trial.
    Martinón-Torres F; Carmona Martinez A; Simkó R; Infante Marquez P; Arimany JL; Gimenez-Sanchez F; Couceiro Gianzo JA; Kovács É; Rojo P; Wang H; Bhusal C; Toneatto D
    J Infect; 2018 Mar; 76(3):258-269. PubMed ID: 29253560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 Studies.
    Beeslaar J; Absalon J; Anderson AS; Eiden JJ; Balmer P; Harris SL; Jones TR; O'Neill RE; Pregaldien JL; Radley D; Maansson R; Ginis J; Srivastava A; Perez JL
    Infect Dis Ther; 2020 Sep; 9(3):641-656. PubMed ID: 32700260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modeling persistence of hSBA titers over time following a primary series and a booster dose of MenB-FHbp.
    Cai B; Peyrani P; Beeslaar J; Burman C; Balmer P
    Vaccine; 2023 Apr; 41(17):2729-2733. PubMed ID: 37024411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meningococcal serogroup B vaccines: Estimating breadth of coverage.
    Donald RG; Hawkins JC; Hao L; Liberator P; Jones TR; Harris SL; Perez JL; Eiden JJ; Jansen KU; Anderson AS
    Hum Vaccin Immunother; 2017 Feb; 13(2):255-265. PubMed ID: 27960595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bivalent rLP2086 Vaccine (Trumenba(®)): A Review in Active Immunization Against Invasive Meningococcal Group B Disease in Individuals Aged 10-25 Years.
    Shirley M; Dhillon S
    BioDrugs; 2015 Oct; 29(5):353-61. PubMed ID: 26394633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents.
    Vesikari T; Østergaard L; Diez-Domingo J; Wysocki J; Flodmark CE; Beeslaar J; Eiden J; Jiang Q; Jansen KU; Jones TR; Harris SL; O'Neill RE; York LJ; Crowther G; Perez JL
    J Pediatric Infect Dis Soc; 2016 Jun; 5(2):152-60. PubMed ID: 26407272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents.
    Vesikari T; Wysocki J; Beeslaar J; Eiden J; Jiang Q; Jansen KU; Jones TR; Harris SL; O'Neill RE; York LJ; Perez JL
    J Pediatric Infect Dis Soc; 2016 Jun; 5(2):180-7. PubMed ID: 26803328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study.
    Santolaya ME; O'Ryan ML; Valenzuela MT; Prado V; Vergara R; Muñoz A; Toneatto D; Graña G; Wang H; Clemens R; Dull PM;
    Lancet; 2012 Feb; 379(9816):617-24. PubMed ID: 22260988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune Responses to Booster Vaccination With Meningococcal ABCWY Vaccine After Primary Vaccination With Either Investigational or Licensed Vaccines: A Phase 2 Randomized Study.
    Szenborn L; Block SL; Jackowska T; Konior R; D'Agostino D; Smolenov I; Toneatto D; Welsch JA
    Pediatr Infect Dis J; 2018 May; 37(5):475-482. PubMed ID: 29329168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials.
    Vesikari T; Esposito S; Prymula R; Ypma E; Kohl I; Toneatto D; Dull P; Kimura A;
    Lancet; 2013 Mar; 381(9869):825-35. PubMed ID: 23324563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis.
    Flacco ME; Manzoli L; Rosso A; Marzuillo C; Bergamini M; Stefanati A; Cultrera R; Villari P; Ricciardi W; Ioannidis JPA; Contopoulos-Ioannidis DG
    Lancet Infect Dis; 2018 Apr; 18(4):461-472. PubMed ID: 29371070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trial.
    Martinón-Torres F; Safadi MAP; Martinez AC; Marquez PI; Torres JCT; Weckx LY; Moreira ED; Mensi I; Calabresi M; Toneatto D
    Vaccine; 2017 Jun; 35(28):3548-3557. PubMed ID: 28533054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine.
    Perez JL; Absalon J; Beeslaar J; Balmer P; Jansen KU; Jones TR; Harris S; York LJ; Jiang Q; Radley D; Anderson AS; Crowther G; Eiden JJ
    Expert Rev Vaccines; 2018 Jun; 17(6):461-477. PubMed ID: 29883226
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and Safety of Investigational MenABCWY Vaccine and of 4CMenB and MenACWY Vaccines Administered Concomitantly or Alone: a Phase 2 Randomized Study of Adolescents and Young Adults.
    Beran J; Dražan D; Enweonye I; Bhusal C; Toneatto D
    mSphere; 2021 Dec; 6(6):e0055321. PubMed ID: 34787449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp.
    Burman C; Alderfer J; Snow VT
    J Clin Pharm Ther; 2020 Apr; 45(2):270-281. PubMed ID: 31820483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and safety of concomitant administration of meningococcal serogroup B (4CMenB) and serogroup C (MenC-CRM) vaccines in infants: A phase 3b, randomized controlled trial.
    P Safadi MA; Martinon-Torres F; Weckx LY; Moreira ED; da Fonseca Lima EJ; Mensi I; Calabresi M; Toneatto D
    Vaccine; 2017 Apr; 35(16):2052-2059. PubMed ID: 28318767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age.
    Snape MD; Voysey M; Finn A; Bona G; Esposito S; Principi N; Diez-Domingo J; Sokal E; Kieninger D; Prymula R; Dull PM; Kohl I; Barone M; Wang H; Toneatto D; Pollard AJ;
    Pediatr Infect Dis J; 2016 Apr; 35(4):e113-23. PubMed ID: 26756390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.
    Findlow J; Borrow R; Snape MD; Dawson T; Holland A; John TM; Evans A; Telford KL; Ypma E; Toneatto D; Oster P; Miller E; Pollard AJ
    Clin Infect Dis; 2010 Nov; 51(10):1127-37. PubMed ID: 20954968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents.
    Saez-Llorens X; Aguilera Vaca DC; Abarca K; Maho E; Graña MG; Heijnen E; Smolenov I; Dull PM
    Hum Vaccin Immunother; 2015; 11(6):1507-17. PubMed ID: 25969894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years.
    Borja-Tabora CFC; Peyrani P; Webber C; Van der Wielen M; Cheuvart B; De Schrevel N; Bianco V; Aris E; Cutler M; Li P; Perez JL
    BMC Infect Dis; 2020 Jun; 20(1):426. PubMed ID: 32552685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.